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Abstract  
Alkylresorcinols (AR) are amphiphilic phenolic lipids that are extensively metabolized 
in the liver and form metabolites that can be detected in plasma and urine. Two AR 
metabolites, 3,5-dihydroxybenzoic acid (DHBA) and 3-(3,5-dihydroxyphenyl)-
propanoic acid (DHPPA), have been evaluated as urinary biomarkers of whole grain 
wheat and rye intake. AR metabolite concentrations are currently measured by 
chromatographic techniques but for samples from large epidemiological studies, 
immunoassay techniques are preferred due to rapid and cheap analysis. The aim of this 
thesis was to develop high-throughput analytical methods for the analysis of 
alkylresorcinol metabolites and to evaluate recently discovered putative metabolites 
3,5-dihydroxycinnamic acid (DHCA), 5-(3,5-dihydroxyphenyl) pentanoic acid 
(DHPPTA), 3,5-dihydroxycinnamic acid amide (DHCA-amide) and 2-(3,5-
dihydroxybenzamido) acetic acid (DHBA-glycine) as biomarkers of whole grain wheat 
and rye intake. 
Polyclonal antibodies against DHBA and DHPPA were produced and characterized 
in terms of cross-reactivity, assay sensitivity, precision and accuracy. A developed 
ELISA method was used for analysis of urine samples and results were compared with 
GC-MS. A lack of agreement was found. Several putative AR metabolites were 
identified by LC-MS/MS, including DHPPTA, DHCA, DHBA-glycine and DHCA-
amide. These compounds showed high cross reactivity in ELISA and likely explains 
the lack of agreement between the two methods. 
The medium-term reproducibility and relative validity of DHCA, DHPPTA and 
DHBA-glycine were found to be moderate to excellent in 24h urine collections. 
Moreover, the reproducibility was good for these metabolites also in spot-urine 
samples. Age and sex were found to be important determinants besides whole grain 
intake. The results suggest that determination of AR metabolites in 24h urine and single 
or duplicate spot urine samples appear to be suitable medium to long-term biomarkers 
of whole grain wheat and rye intake. These findings need to be confirmed in other 
populations before using these biomarkers in epidemiological studies. 
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Abbreviations 
3DWFR Three-day weighed food records 
ADHBA 4-amino-3,5-dihydroxybenzoic acid 
AP Alkaline phosphatase 
AR Alkylresorcinols 
DHBA 3,5-dihydroxybenzoic acid 
DHBA-
glycine      
2-(3,5-dihydroxybenzamido)acetic acid 
DHCA 3,5-dihydroxycinnamic acid 
DHCA-
amide        
3,5-dihydroxycinnamic acid amide 
DHPAA 3,5-dihydroxyphenyl acetic acid 
DHPPA    3-(3,5-dihydroxyphenyl)-propanoic acid 
DHPPTA   5-(3,5-dihydroxyphenyl) pentanoic acid 
ELISA Enzyme-linked immunosorbent assay 
WG Whole grain 
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1 Background 
It is widely accepted that diet, along with other lifestyle factors, has a major 
impact on human health (Millen et al., 2016; Mozaffarian, 2016; Anand et al., 
2015; Ross et al., 2015; Conlon & Bird, 2014; Linko et al., 2005a). It has been 
estimated that diet and lifestyle factors explain about 80% of the deaths from 
cardiovascular disease world-wide and over one-third of cancers (Celis-
Morales et al., 2016). Cereal grains constitute the primary source of energy and 
protein intake world-wide and have therefore played an important role of the 
human diet for thousands of years (Spiller, 2002). Today, most cereals are 
consumed as refined grains, but refined grains only started to dominate cereal 
consumption around 100 years ago (Slavin, 2007). From a health perspective, 
grains should preferably be consumed whole. Epidemiological studies have 
consistently shown inverse associations between whole grain cereal intake and 
the risk of developing obesity (Kirwan et al., 2016; Pol et al., 2013), type 2 
diabetes (Chanson-Rolle et al., 2015; Aune et al., 2013), cardiovascular disease 
(Wei et al., 2016; Tang et al., 2015), and some cancers (Aune et al., 2016; 
Meija et al., 2015). 
Whole grain refers to “intact, ground, cracked or flaked caryopsis, whose 
principal anatomical components – the starchy endosperm, germ and bran – are 
present in the same relative proportions as they exist in the intact caryopsis” 
(definition by AACC, 1999). In contrast, refined grains have the bran and germ 
removed during the milling process (Fardet, 2010). Therefore, the nutritional 
value of refined grains is considerably lower than that of whole grain cereals, 
which are rich in minerals, vitamins, dietary fibre and many bioactive 
compounds (Andersson et al., 2014). The most common whole grain cereals 
consumed world-wide are wheat, rice and maize, followed by oats, rye, barley, 
triticale, millet and sorghum (Fardet, 2010). 
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Assessing whole grain food intake is complicated due to the different 
definitions of whole grain used, large variations in whole grain content in 
cereal foods, lack of food composition data and because consumers have 
difficulty distinguishing whole grain foods from other products (Ross et al., 
2015; Lang & Jebb, 2003). Moreover, most studies relying on self-reported 
intake data, such as 24-h recalls or food frequency questionnaires (FFQ) 
(Kaaks & Ferrari, 2006; Kaaks et al., 2002), are known to suffer from large 
systematic and random measurement errors (Tasevska et al., 2011; Kaaks et 
al., 2002). Thus, there is a need for dietary biomarkers that can provide an 
objective measure of intake and complement self-reported methods in 
assessment of intake of whole grain foods (Holen et al., 2016b). Using dietary 
biomarkers in large-scale epidemiological studies in relation to disease 
endpoints requires large sample sets to be analysed. Therefore rapid, accurate, 
sensitive and low-cost methods are highly warranted.  
1.1 Alkylresorcinols and their occurrence  
Alkylresorcinols (AR), are amphiphilic 1,3-dihydroxy-5-alkyl phenolic lipids, 
have been proposed as specific dietary biomarkers of whole grain wheat and 
rye intake (Landberg et al., 2014; Ross, 2012). Two AR metabolites 1,3-
dihydroxy-benzoic acid (DHBA) and 3-(3,5-dihydroxyphenyl)-1-propanoic 
acid (DHPPA) have been quantified in urine  in free form and as a mixture of 
aglycones and glucuronide and sulphate conjugates(Ross et al., 2004c) In a 
recent study, 5-(3,5-dihydroxyphenyl) pentanoic acid (DHPPTA) and 2-(3,5-
dihydroxybenzamido)acetic acid (DHBA–glycine) were suggested as 
metabolites from ARs (Zhu et al., 2014). 
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Alkylresorcinols Alkylresorcinol metabolites 
5-n-heptadecyl resorcinol, R=C17:0  
5-n-nonadecyl resorcinol, R=C19:0  
5-n-heneicosyl resorcinol, R=C21:0 
5-n-tricosyl resorcinol, R=C23:0 
5-n-pentacosyl resorcinol, R=C25:0 
DHBA, R= COOH 
DHPPA, R=CH2CH2COOH 
DHPPTA, R=(CH2)4COOH 
DHBA-glycine, R=CONHCH2COOH 
 
Figure 1. (Left) structure of common alkylresorcinols present in wheat and rye grains and (right) 
four putative urinary metabolites in humans. 
Alkylresorcinols have been found in bacteria, fungi, algae, mosses, higher 
plants and animals (Haliclonidae) (Kozubek & Tyman, 1999). Among plants 
commonly consumed by humans, odd-numbered AR have been found in high 
amounts in grain of rye (Secale cereale), wheat (Triticum aestivum) and the 
rye-wheat hybrid triticale, and in low amounts in barley (Hordeum vulgare) 
and millet (Andersson et al., 2008; Chen et al., 2004; Zarnowski & Suzuki, 
2004; Ross et al., 2003c; Kozubek & Tyman, 1999).   
Alkylresorcinols are found mainly in the outer part of the grain (Ross et al., 
2003c) or, more precisely, in the cuticulum of the testa/inner cuticulum of the 
pericarp (Landberg et al., 2008b), but not in large amounts in refined grains or 
in other food products (Chen et al., 2004). Alkylresorcinol homologues with 
odd alkyl chains of 17-25 carbon atoms are the most common AR compounds 
in cereal grains, though unsaturated derivatives such as 5-alkenyl-, 5-oxoalky- 
and 5-hydroxyalkylresorcinols are also found, particularly in rye (Kozubek & 
Tyman, 1999). In addition, even-numbered AR homologues (C18:0, C22:0 and 
C24:0) have recently been identified in quinoa (Chenopodium quinoa) (Ross, 
2014).  
The source of whole grain in food products can be distinguished by 
determination of the AR C17:0/C21:0 ratio, which is 1.0 in whole grain rye, 
0.1 in whole grain wheat and 0.01 in whole grain durum wheat (Landberg et 
al., 2006a; Chen et al., 2004). The AR content in rye is 268-1444 µg/g dry 
matter (DM) and in wheat 220-943 µg/g (DM), while the content in refined rye 
flour is 40-280 µg/g DM and in refined wheat flour at most 50 µg/g DM 
(Landberg et al., 2014). Average daily intake ranges from 12 mg in the United 
Kingdom to nearly 40 mg in Finland (Ross, 2012).  
OH
OH R
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1.2  Alkylresorcinol absorption, distribution, metabolism and 
excretion (ADME) 
1.2.1 Alkylresorcinols absorption  
Animal and human studies have shown that AR are absorbed to a great extent 
in the small intestine and metabolised before excretion in urine (Ross et al., 
2004c). The apparent absorption of AR is 60-80%, as determined in 
ileostomised humans (Ross et al., 2003a) and cannulated pigs and rats (Ross et 
al., 2003b). Alkylresorcinol absorption varies between individuals and animal 
models (Landberg et al., 2014) depending on the intake level, but not with 
intake frequency. It appears that the absorption differs slightly between 
different AR homologues, with shorter alkyl-chain homologues being absorbed 
to a greater extent that those with a longer alkyl chain (Landberg et al., 2009a; 
Ross et al., 2004c).  
The cellular mechanism(s) of AR absorption in the small intestine is 
still unknown. Similarly to tocopherols, AR may be absorbed by passive 
diffusion and  to some extent actively by scavenger receptor class B (SR-BI) 
(Rigotti, 2007). The majority of ingested AR are absorbed in the small intestine 
and transported in chylomicrons via the lymphatic system to the liver, where 
they are mainly incorporated into very-low-density lipoprotein (VLDL) or 
high- density lipoprotein (HDL), as also reported for tocopherols (Linko-
Parvinen et al., 2007). In a complementary mechanism, AR could possibly be 
directly transported from chylomicrons to HDL or VLDL during lipolysis 
(Linko-Parvinen et al., 2007). Incorporation into chylomicrons and direct 
outflow to HDL have been suggested for tocopherols, with availability of fat as 
a decisive factor (Anwar et al., 2006). 
1.2.2 Alkylresorcinol distribution 
The amphiphilic structure of AR makes them easy to incorporate into 
biological membranes, where they can modify functions and properties 
(Kozubek, 1989). It has been observed that long-chain AR are incorporated 
more easily into membranes and diffuse faster across membranes than short 
chain AR (Linko & Adlercreutz, 2005; Kozubek, 1989). Moreover, studies in 
humans and rats have confirmed that AR are incorporated into erythrocyte 
membranes (Linko & Adlercreutz, 2005; Ross et al., 2003b). More recently, 
AR have been shown to accumulate in adipose tissue in rats and humans (Wu 
et al., 2015; Jansson et al., 2010; Ross et al., 2004b), while whole grain intake 
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has been shown to be correlated with AR content in adipose tissue in analyses 
under controlled conditions (Wu et al., 2015). The distribution of AR in other 
organs or tissues is unknown. 
1.2.3 Alkylresorcinol metabolism 
Alkylresorcinol metabolism shares similarities with tocopherol metabolism, 
which consists of two phases: an oxidative step (phase 1) and a conjugation 
reactions (phase 2) (Marklund., 2012; Ross et al., 2004a). AR metabolites: 1,3-
dihydroxybenzoic acid (DHBA) and 3-(3,5-dihydroxyphenyl)-1-propanoic acid 
(DHPPA) have been detected and quantified as a mixture of aglycones and 
glucuronide and sulphate conjugates in urine (Zhu et al., 2016; Hanhineva et 
al., 2015; Marklund et al., 2010; Ross et al., 2004a). More recently, 5-(3,5-
dihydroxyphenyl) pentatonic acid (DHPPTA) and 2-(3,5-dihydroxybenzamido) 
acetic acid (DHBA-glycine) have also been described as urinary metabolites 
derived from AR (Zhu et al., 2014). Moreover, an untargeted urine metabolite 
profiling study has identified a sulphated conjugate of 3,5-dihydroxycinnamic 
acid (DHCA) after a whole grain rye bread intervention and suggests to be  a 
metabolite from AR (Bondia-Pons et al., 2013). 
 
Phase I metabolism 
The first step in AR metabolism is the introduction of a hydroxyl (-OH) 
group at the end of the alkyl chain through omega (ω) oxidation (Ross et al., 
2004c). This process is catalysed by cytochrome P450 isoenzyme CYP4F2 
(Marklund et al., 2013b; Ross et al., 2004c) and is probably located in the 
endoplasmic reticulum and cytoplasm (Mustacich et al., 2010). The ω-
hydroxyl group is then oxidised to a carboxylic acid. The carboxylic acid is 
further activated to an acyl-CoA ester that undergoes β-oxidation. During beta 
β-oxidation, the alkyl chain is gradually shortened, by two carbons at a time, to 
DHPPA and DHBA as final products (Ross et al., 2004c) (Figure 2). 
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Figure 2. Suggested metabolic pathway of alkylresorcinols (AR), represented by AR C17:0 degraded to 
3,5-dihydroxybenzoic acid (DHBA) and 3-(3,5-dihydroxyphenyl)-propanoic acid) (DHPPA) (Ross et 
al., 2004c), and to 5-(3,5-dihydroxyphenyl) pentanoic acid (DHPPTA), recently presented as an AR 
metabolite (Zhu et al., 2014).  
 
Phase II metabolism 
The end products of β-oxidation are converted to water-soluble AR metabolites 
that are partially conjugated by phase II metabolism before urinary excretion 
(Ross et al., 2004a). In phase II, excretion properties are improved by 
conjugation of a polar group to xenobiotics or endogenous compounds. 
Glucuronidation, sulfation and amino acid conjugation are the main reactions 
COOH
OH
OH
OH
OH
OH
CH3OH
OH
COOHOH
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COOH
OH
OH
DHPPTA
COOH
OH
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in phase II metabolism (Knights et al., 2011; Zamek-Gliszczynski et al., 2006). 
Glucuronidation involves conjugation of endogenous compounds, xenobiotics 
or their metabolites with a glucuronic acid (Zamek-Gliszczynski et al., 2006). 
This reaction is catalysed by uridine 5′-diphosphate (UDP)-
glucuronosyltransferase enzymes, which transfer glucuronic acid from a co-
substrate, UDP-glucuronic acid, to the substrate (Kutsuno et al., 2013). Based 
on evolutionary diversity, UGT1 and UGT2 are two subfamilies of the UGT 
enzyme. In mammals such as humans, mice and rats, UGT1 is present. The 
UGT enzymes are found in the endoplasmic reticulum of different tissues, with 
liver as a major site for glucuronide conjugation (Katoh et al., 2007). Some of 
the glucuronide conjugates can be deconjugated in acidic environments, since 
the glucuronidation process is reversible. In vivo, deconjugation reactions are 
mediated by β-glucuronidase (Zamek-Gliszczynski et al., 2006).  
Sulphation is a conjugation with a sulpho-group catalysed by 
sulphotransferase enzyme(s). Sulphotransferase applies 3'-phosphoadenosine-
5'-phosphosulphate (PAPS) as a co-substrate to covalently attach sulphonic 
acid to hydroxyl or amine groups of the substrate (Strott, 2002). 
Sulphotransferase is available mainly in the liver, but can also be found in the 
intestine, kidney and other tissues. In most cases, addition of the sulphone 
moiety to the compound increases the solubility and decreases the biological 
activity (Gamage et al., 2006). 
Less is known about amino acid conjugation than about glucuronidation and 
sulphation reactions. Amino acid conjugation is limited to a number of 
carboxylic acids: aryloxyacetic, arylacetic, aromatic and heteroaromatic acid 
(Knights et al., 2011; Pacifici et al., 1991). Glycine is the most common amino 
acid utilised as an aglycone acceptor in amino acid conjugation in humans. 
Unlike the other conjugation reactions, amino acid conjugation comprises two 
enzyme systems that operate in two steps:  
Activation of the carboxylic acid moiety with adenosine triphosphate (ATP) 
and formation of reactive xenobiotic CoA thioester intermediate mediated by 
ATP-dependent acid:CoA synthetase (ACSM).  
Transfer of the activated acyl group to the amino group of glycine. This 
reaction is catalysed by the acyl-CoA:amino acid N-acyltransferase (Knights et 
al., 2007; Pacifici et al., 1991). 
Glycine conjugation is readily saturable and metabolism of some carboxylic 
acids is therefore dose-dependent. Relatively few drugs and chemicals are 
activated to acyl-Co A thioester and their alkyl- or alkxyl- chain position plays 
an important role in the conjugation process. It has been observed for benzoic 
acids that the para- or meta- chain position exhibits the highest activity when 
ortho-situated benzoic acid is not able to conjugate to acyl-CoA esters (Knights 
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et al., 2011). Moreover, in vivo studies have shown that human liver and 
kidney homogenates from newborns have a limited capacity to form glycine 
conjugates of benzoic and p-amino-benzoic acid and that the possibility for 
glycine conjugation decreases with age (Knights et al., 2011). As mentioned, 
DHBA-glycine has recently been detected and described as an AR urinary 
metabolite (Zhu et al., 2014). 
Recent studies using three in vitro platforms: human cytochrome P450 4F2 
(CYP4F2), human liver S9 and HepG2 incubated with C19:0 cells, have 
confirmed suggested metabolic pathways whereby AR are transformed to 
phenolic lipids via CYP4F2-mediated ω-oxidation and subsequent β-oxidation 
(Marklund et al., 2013b). To date, no conjugated AR have been found in 
plasma, which indicates that ω-oxidation is placed before the conjugation 
reaction in the AR metabolic pathway or that AR phase II metabolism is not 
sufficient to excrete the conjugated metabolites to the circulatory system 
(Landberg et al., 2014). However, small amounts of intact AR have been 
detected in urine after β-glucuronidase and sulphatase deconjugation. This 
indicates that phase I and phase II metabolism of AR may occur in parallel, as 
has been observed for tocopherols, or that AR homologues may undergo a 
conjugation reaction (Hashiguchi et al., 2011). Both DHBA and DHPPA have 
been detected in plasma and urine in free form as a product and as a mixture of 
aglycones or conjugates (Marklund et al., 2012; Koskela et al., 2008). 
Moreover, it could be speculated that DHBA-glycine is formed from DHBA 
through the amino acid conjugation performed in phase II metabolism.  
1.2.4 Alkylresorcinol excretion 
The AR metabolites DHBA and DHPPA are mainly eliminated from the body 
by urinary excretion (Ross et al., 2004a). In a recent study, DHBA and DHPPA 
were recovered in ileostomy effluent from four ileostomised subjects 
consuming rye bran and it was found that 20-25% of ingested AR appeared as 
two main AR metabolites in the ileostomy effluent (mostly as DHPPA) 
(Marklund et al., 2014b). This suggests that biliary excretion is an important 
route of AR metabolite elimination (Landberg et al., 2014; Marklund et al., 
2014b). However, it is unknown to what extent other metabolites are excreted 
through this route. The quantitative recovery of ingested AR excreted as 
metabolites in urine is higher at lower AR intake (90%). It may be explained 
by a change in the elimination route and/or decreased absorption at high doses 
(Landberg et al., 2009d; Landberg et al., 2006). This is supported by a 
previous finding of AR metabolites undergoing enterophatic circulation at high 
intake (Soderholm et al., 2009). 
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Figure 3. Suggested alkylresorcinol (AR) metabolic pathway in humans (Marklund et al., 2014b): 
Following uptake from the intestine to the gut wall (A), AR are transferred to the circulatory 
system through the portal vein (B) or lymphatic pathway (C). Portal absorption delivers AR to the 
liver (D), where a proportion is metabolised to 3,5-dihydroxybenzoic acid (DHBA) and 3-(3,5-
dihydroxyphenyl)-propanoic acid (DHPPA) before entering the circulatory system (E). 
Lymphatic absorption of AR is slower, but AR absorbed through this pathway are not subjected 
to hepatic metabolism (F). Alkylresorcinols may be metabolised in the gut wall and excreted to 
the intestinal lumen (G). In the circulatory system, AR are mostly present in lipoprotein particles 
(H) and erythrocytes (I), but can be reversibly transferred to e.g. adipose tissue (J) or liver (K). In 
the liver, AR can be reassembled to different lipoproteins (L) or undergo phase I and II 
metabolism (M). Metabolites such as DHPPA and possibly conjugated AR are excreted via the 
bile (N) to the intestine (O), where they are available for reabsorption (P). After formation in the 
liver, DHBA and DHPPA are secreted (Q) into plasma and can be rapidly eliminated by the 
kidneys (R) to the urine (S). If not reabsorbed, intact AR and their metabolites excreted from the 
gut wall and bile eventually appear in faeces (T). The figure was re-produced by permission from  
Journal of Nutrion 
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1.3 Alkylresorcinols and their metabolites as dietary biomarkers 
1.3.1 Dietary biomarkers 
Dietary biomarkers (DB) are biochemical, functional or clinical indicators that 
reflect intake or status of certain foods or nutrients (Combs et al., 2013). 
Dietary biomarkers may provide an objective measure of intake of a specific 
compound, nutrient, food or diet and have the potential to provide a more 
accurate intake assessment, which could improve chronic disease risk 
prediction in epidemiological studies (Aubertin-Leheudre et al., 2010a; 
Bingham et al., 2008). Dietary biomarkers can be classified into three different 
categories, concentration, recovery and prediction, depending on their 
relationship with intake (Tasevska et al., 2006; Kaaks et al., 2002).  
Concentration biomarkers are based on measurement of a nutrient or 
compound concentration at a given point in time. They are correlated to intake, 
but do not offer a quantitative measurement as recovery biomarkers, since 
factors other than intake also affect their concentration. Variations in digestion, 
absorption and distribution in body compartments, excretion and endogenous 
synthesis and metabolism affect the concentration of these biomarkers 
(Freedman et al., 2010a; Kaaks et al., 2002). Serum fatty acids, plasma vitamin 
C and carotenoids as markers for fat, fruit and vegetable intake, respectively, 
are examples of classical concentration biomarkers (Bingham et al., 2008; 
Wolk et al., 2001; Kaaks et al., 1997). 
Recovery biomarkers are based on a quantitative relationship between 
intake and output in a specific period and offer an absolute measurement of a 
subject’s intake (Kaaks et al., 2002). Examples of recovery biomarkers 
include: double-labelled water as a marker for energy intake (Livingstone & 
Black, 2003) and 24-h urinary excretion of nitrogen and potassium as a marker 
for protein  (Bingham, 2003) and potassium intake (Tasevska et al., 2006), 
respectively. Recovery biomarkers can be useful in validation studies as a 
reference method, since they can be quantitatively measured and compared 
with conventional dietary assessment methods on the same scale (Kaaks et al., 
1997). They can also be used to study the measurement error structure of 
conventional intake assessment tools and for regression calibration studies 
(Spiegelman et al., 2005). However, biomarkers are not without limitations. 
Only a very limited number of such biomarkers exist to reflect a few dietary 
factors and they typically reflect intake over short time periods (Willett., 2012).  
Prediction biomarkers, unlike recovery biomarkers, only account for a small 
proportion of the intake recovered, but the correlation to intake is relatively 
strong, time-related and sensitive in a dose-response manner and the impact of 
non-dietary determinants is smaller than for concentration biomarkers. In 
21 
general, prediction biomarkers are characterised by high reproducibility, high 
correlation with intake and high predictive potential (Tasevska et al., 2011; 
Tasevska et al., 2005). Therefore, they can be classified as an intermediate 
between recovery and concentration biomarkers. 
1.3.2 Biomarker validity and reproducibility 
Validity and reproducibility are two critical features in assessment of dietary 
biomarkers. Validity can be reflected by the correlation between biomarker 
measurement and true intake. Despite the inherent weaknesses of any dietary 
assessment method, food records have often been used as a surrogate of ‘true’ 
intake and correlation of the biomarker to surrogate measurements has been 
taken to indicate relative validity (Eysteinsdottir et al., 2012).  Validation of a 
biomarker is a necessary stage in obtaining high-quality research data (Hunter 
et al., 2010). A valid biomarker has been defined as "a biomarker that is 
measured in an analytical test system with well-established performance 
characteristics and for which there is an established scientific framework or 
body of evidence that elucidates the physiological, toxicological, 
pharmacological, or clinical significance of the test results"(Hunter et al., 
2010).  
Validation is the process of “assessing the biomarker and its measurement 
performance characteristics, and determining the range of conditions under 
which the biomarker will give reproducible and accurate data” (Hunter et al., 
2010). Validation of any biomarker should be performed based on the 
analytical, biological and utilisation steps (Odriozola & Corrales, 2015a).  
Reproducibility reflect the stability of the biomarker over time, based on the 
correlation between repeated measurements within the same individual, and 
depends on the elimination half-life of the biomarker and the intake frequency 
(van Dam & Hu, 2008; Kaaks et al., 1997). Reproducibility is also dependent 
on the intake range in the population and is assessed by the intra-class 
correlation coefficient (ICC), defined as the ratio of between-participant 
variance to total variance (Vineis, 1997). The ICC ranges in value between 0.0 
and 1.0, with ICC being equal to 1.0 if there is exact agreement between 
repeated measures within the same individual (Landberg et al., 2014). The 
reproducibility can be considered good when ICC is >0.4-0.5 (Sun et al., 
2017). A long-term biomarker exhibits high ICC over months or even a year 
(Kaaks, 1997). Stable and regular intake may compensate for a short half-life 
of a biomarker (van Dam & Hu, 2008). 
When developing a potential dietary biomarker, factors that may not be 
important in conventional assessment methods, but which may affect 
biomarker measurement, need to be taken into consideration and evaluation.  
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Such  factors include genetic variability, lifestyle/physiological factors (e.g. 
smoking), dietary factors (e.g. nutrient-nutrient interaction), analytical 
methodology and biological sample handling (Hedrick et al., 2012). Therefore, 
various stakeholders such as academia, the food industry, regulation agencies 
and the health sector should be involved in biomarker development and 
validation, in order to improve understanding of the connection between 
dietary biomarkers and endpoints (Odriozola & Corrales, 2015a; Jenab et al., 
2009). 
1.3.3 Application of dietary biomarkers in food and health studies 
Dietary biomarkers can be used in observational studies to examine the 
relationship between diet and diseases (Ross et al., 2015) and in intervention 
studies to check compliance (Holen et al., 2016a; Mayne et al., 2016; 
Marklund et al., 2014a). When a biomarker is used as a measure of 
exposure/intake in epidemiological studies, it should preferably reflect the 
intake during the time window in which the disease under study develops. 
Typically, it takes years to develop a chronic disease and thus high long-term 
reproducibility is highly desirable for most dietary biomarkers in 
epidemiological studies (Landberg et al., 2014).  
When using dietary biomarkers to measure dietary compliance in dietary 
intervention studies (McKeown et al., 2016; Marklund et al., 2014a), they can 
be used in secondary analyses to study the effect after removing non-compliant 
subjects and to improve motivation through participants knowing that their 
records can be cross-checked by biomarker measurements on biological 
samples (Ross, 2012). Recent studies have confirmed the potential for using 
dietary biomarkers in dietary intervention studies (Kristensen et al., 2017; 
Marklund et al., 2014a; Landberg et al., 2009b). 
Moreover, dietary biomarkers can potentially be used to validate dietary 
assessment methods and to reflect dietary intake when self-reports are lacking 
or when food composition tables are inadequate (Hedrick et al., 2012). A 
combination of dietary biomarkers and self-reported methods could, under 
certain circumstances, be used to improve the precision in diet-disease 
association studies (Freedman et al., 2010b).  
A few biomarkers of whole grain and dietary fibre have been suggested. 
One of the first was the mammalian lignin enterolactone (ENL). Enterolactone 
is produced by gut microbiota from its precursors, i.e. plant lignans, and has 
been proposed as a biomarker of whole grain intake (Peterson et al., 2010; 
Adlercreutz, 2007). However, since ENL precursors are also found in large 
amounts in other foods, such as coffee, and because of the great impact of 
antibiotics and non-dietary determinants, it has been suggested to be at best a 
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biomarker of a healthy lifestyle (Seibold et al., 2014; Adlercreutz, 2007; 
Linko-Parvinen et al., 2007; Horner et al., 2002; Kilkkinen et al., 2001). More 
recently, AR and their metabolites DHBA and DHPPA have been proposed 
and evaluated as specific dietary biomarkers of whole grain wheat and rye 
intake (Landberg et al., 2014; Ross et al., 2012a; Ross et al., 2004a).  
Untargeted metabolomics has recently proven to be a powerful approach in 
the discovery of novel putative biomarkers of whole grain foods (Sang, 2016); 
(Zhu et al., 2016; Hanhineva et al., 2015; Odriozola & Corrales, 2015b). In a 
recent study, several specific biomarkers of whole grain rye were suggested 
(Hanhineva et al., 2015). However, any novel biomarker or biomarker panel 
needs to be validated before implementation and so far validation has only 
been reported for AR and their metabolites. 
1.3.4 Alkylresorcinols as dietary biomarkers 
Alkylresorcinol molecules are stable and remain intact throughout food 
processing (Chen et al., 2004). They are also specific to the outer parts of 
wheat and rye grains, are absorbed by humans and are measurable in human 
samples. Moreover, recent studies on reproducibility and relative validity of 
AR and their metabolites demonstrated that they can be used as biomarkers of 
whole grain wheat and rye intake (Marklund et al., 2013a; Andersson et al., 
2011a). However, AR metabolites have limitations as biomarkers in 
epidemiology due to the modest reproducibility in plasma and spot urine 
samples and lack of 24 h urine samples in large observational studies 
(Marklund., 2012).   
A number of studies have been undertaken to evaluate plasma AR 
homologues and plasma and urinary AR metabolites as dietary biomarkers of 
whole grain wheat and rye intake (McKeown et al., 2016; Kyro et al., 2014; 
Zhu et al., 2014; Landberg et al., 2013; Ross et al., 2012a; Aubertin-Leheudre 
et al., 2010a). Most of these studies have been conducted in the Nordic 
countries, where consumption of whole grain, especially rye, is high and 
frequent (Landberg et al., 2012). Some studies have also evaluated AR as 
biomarkers in populations where consumption of whole grain products is lower 
and mainly consists of wheat products (McKeown et al., 2016; Landberg et al., 
2012).  
Total plasma AR homologues are generally well correlated to whole grain 
and cereal fibre intake under controlled intervention conditions and under free-
living conditions (Landberg et al., 2013; Ross et al., 2012a; Landberg et al., 
2011; Landberg et al., 2009d; Linko et al., 2005a).  Moreover, the source of 
whole grains in food products can be distinguished by determination of the AR 
C17:0/C21:0 ratio. Hence AR homologues in plasma can be used as 
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biomarkers to trace the source of whole grain intake (rye/wheat)(Landberg et 
al., 2008a). This opens up new possibilities to examine the health effects of 
different kinds of grain.  
In human studies, the half-life of AR in plasma is estimated to be around 5 
h and the maximum AR concentration is >3000 nmol/L (Landberg et al., 
2006). Consequently, AR reflect short to medium-term intake. On the other 
hand, AR have slow absorption (tmax = 6.7 h) and therefore if the whole grain is 
consumed more than once per day, fluctuations in plasma AR concentrations 
are dampened and under such conditions plasma AR concentration can be 
considered a long-term biomarker (Landberg et al., 2014). Consequently, in the 
Nordic population with reported high and frequent whole grain intake, fasting 
AR plasma concentration shows moderate to high reproducibility (ICC=0.47-
0.9) under controlled and regular whole grain consumption, as well as under 
free-living conditions (Landberg et al., 2013; Landberg et al., 2009b). Based 
on this, AR concentrations in plasma can be classified as specific concentration 
biomarkers of whole grain wheat and rye intake (Kyro et al., 2014; Landberg et 
al., 2008a). In fact, they have been successfully used as such in relation to 
disease endpoints in epidemiological studies and as a measure of compliance in 
whole grain intervention studies (Biskup et al., 2016; Kirwan et al., 2016; 
Knudsen et al., 2014; Kyro et al., 2014; Marklund et al., 2014a). Recently, AR 
in adipose tissue has been suggested as a long-term biomarker of whole grain 
intake (Wu et al., 2015; Jansson et al., 2010). 
Moreover, it has been suggested that DHBA and DHPPA AR metabolites in 
plasma have longer elimination half-life (10 h for DHBA and 16 h for DHPPA) 
than intact AR and might therefore be better long-term biomarkers than intact 
AR (Soderholm et al., 2009). However, the half-life of the metabolite can also 
reflect its formation half-life from intact AR. Moreover, non-dietary 
determinants may affect metabolite concentrations and this can affect the 
reproducibility negatively. Hence, metabolites may be less useful than intact 
AR (Montonen et al., 2012). 
 
Alkylresorcinol metabolites in urine as biomarkers 
The ease of urine sample collection and the minimal interference in 
participants’ daily life makes urine a suitable matrix for exposure biomarker 
assessment. Urine provides a cumulative biomarker measurement (Marklund et 
al., 2013a). The use of 24-h urine samples avoids the extraneous variability in 
biomarkers due to very short-term changes in exposure and the timing of 
sample collection. A spot urine sample, like a plasma sample, provides a 
snapshot of the biomarker concentration. Adjustment for differences in 
dilution, using creatinine, is generally necessary and improves the precision, 
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despite this measurement also being subject to within-person variability and 
dependent on individuals’ meat intake (Sun et al., 2017). Typically, 24-h urine 
samples are not available in large epidemiological studies, but spot urine 
samples may be available to a greater extent. It is therefore desirable to 
evaluate whether biomarker measurements in such samples are useful for 
independent intake assessment. 
The AR metabolites DHBA and DHPPA in urine have been proposed and 
evaluated as biomarkers of whole grain rye and wheat intake (McKeown et al., 
2016; Landberg et al., 2012; Aubertin-Leheudre et al., 2010a). The apparent 
half-life of DHBA and DHPPA has been found to be longer than that of intact 
AR: 10-12 in urine (Soderholm et al., 2011), indicating that AR metabolites 
can be used as long-term biomarkers. 
In a recent study feeding human subjects whole grain wheat breads 
containing 61 mg AR, DHPPTA and DHBA-glycine in free and conjugated 
form were identified as new AR metabolites in human urine (n=12) and their 
half-life was estimated to be 11.1 and 16.6 h, respectively (Zhu et al., 2014). 
Both DHBA and DHPPA in urine are reported to be well correlated with intake 
of whole grains and cereal fibre (Marklund et al., 2013a; Aubertin-Leheudre et 
al., 2010a; Aubertin-Leheudre et al., 2008). Moreover, urinary excretion of AR 
metabolites is reported to increase with elevated AR intake, although the 
proportion of ingested AR recovered in urine as DHBA and DHPPA decreases 
with increased intake (Landberg et al., 2009d). Excretion of AR metabolites in 
urine samples shows moderate medium-term reproducibility when assessed in 
24-h collection for DHBA (ICC = 0.46-0.51) and lower in creatinine (CR)-
adjusted morning urine for DHPPA (ICC = 0.32-0.37) (Marklund et al., 
2013a). These results are comparable to values reported for fasting plasma AR 
as medium-term biomarkers (Landberg et al., 2012; Andersson et al., 2011b), 
indicating that AR metabolites can also be used as short/medium term 
biomarkers of whole grain intake. 
 In summary, the results obtained to date show that AR concentrations in 
plasma and their metabolites in 24-urine collections and perhaps also in spot 
urine samples are valid and reproducible biomarkers of whole grain wheat and 
rye intake in populations with a regular and high whole grain intake. However, 
there is a need for more long-term biomarkers to be used in populations with 
less frequent intake. 
 
26 
1.4 Chromatographic analysis of alkylresorcinols and their 
metabolites 
To date, several analytical methods have been developed and applied for the 
quantification of AR and AR metabolites in biological matrices such as 
plasma, erythrocyte, adipose tissue and urine (Landberg et al., 2012; Ross et 
al., 2012a; Jansson et al., 2010; Linko-Parvinen et al., 2007). Chromatographic 
methods with different detection means, such as GC-MS (Marklund et al., 
2010), high performance liquid chromatography- coulometric electrode array 
detection (HPLC-CEAD) (Koskela et al., 2008; Koskela et al., 2007), ultra-
performance liquid chromatography-quadrupole time of flight/mass 
spectrometry  (UPLC-QTOF/MS) (Bondia-Pons et al., 2013) and liquid 
chromatography-mass spectrometry (LC-MS) (Zhu et al., 2014), have been 
proven to be useful for analysis of AR and their metabolites because they 
appear at low concentrations in biological samples (nmol-µmol/L range) 
(Andersson et al., 2014). In previous studies, AR homologues in plasma have 
mostly been analysed by GC-MS (Landberg et al., 2009c; Linko et al., 2002). 
More recently, a high-throughput liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) method has been developed and utilised for 
analysis of plasma AR homologues (Ross et al., 2016; Ross et al., 2010). Good 
agreement between GC-MS and LC-MS/MS up to 150 nmol/L has been 
shown, but care is needed when comparing data where plasma AR 
concentrations are expected to be high (Ross et al., 2016).  
Due to a lack of synthetic reference standards for conjugated AR 
metabolites, various conjugated AR metabolites have been hydrolysed with β-
glucuronidase and sulphatase activity before GC-MS analysis (Marklund et al., 
2010). The AR metabolites are then extracted, purified by solid phase 
extraction (SPE) and silylated prior to quantification (Marklund et al., 2010). 
In a later study, (Marklund et al., 2011) compared GC-MS and HPLC-CEAD 
by analysing 114 urine samples from free-living Swedish people consuming 
their habitual diet and concluded that both these methods work similarly and 
can be used interchangeably. However, they also concluded that the analytical 
run time of HPLC-CEAD is longer than that of GC-MS and that purification of 
deconjugated DHBA metabolites is a necessary step due to the interference of 
the co-eluting compounds when using HPLC-CEAD ((Marklund et al., 2011). 
Moreover, in a recent study using an LC-MS approach, DHPPTA and DHBA-
glycine were identified as AR metabolites present at low concentrations in 
urine (Zhu et al., 2014). However, no validation was performed for the method 
used for detection and quantification of DHPPTA and DHBA-glycine in that 
study. Moreover, DHCA-sulphate has been identified in urine from 20 Finnish 
women and men consuming whole grain rye in a study using UPLC-
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QTOF/MS(Bondia-Pons et al., 2013), but could only be quantified on a 
relative basis as no quantitative method is currently available. 
In general, the potential methods for analysis of AR and AR metabolites 
reported to date have been evaluated with regard to assessment of precision, 
linear range and limit of detection, recovery after spiking and quantification 
(Andersson et al., 2014). They have since been successfully applied for rapid, 
sensitive and robust determination of AR and their metabolites in biological 
samples. However, rapid and cheap high-throughput methods suitable for 
analysis of thousands of samples are currently lacking. 
1.5 Immunoassays 
In order to allow rapid and accurate determination of the concentrations of AR 
and their metabolites as biomarkers in large datasets in epidemiological 
investigations, rapid, accurate and sensitive analytical methods are essential. 
Immuno-based techniques may provide such possibilities. 
In general, immunoassays are fast, sensitive methods which allow large 
numbers of samples to be analysed simultaneously and therefore they are 
widely used in clinical chemistry (Kristensen et al., 2016; Weber et al., 1990), 
endocrinology (Chanson et al., 2016; M, 1980), environmental science 
(Ranganathan et al., 2015; Ahn et al., 2011; Deng et al., 2002) and food 
analysis (Liu et al., 2015; Vass et al., 2008; Franek, 2005; Lee et al., 2004). 
Enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and 
fluorescent immunoassay (FIA) are conventional immunoassay methods that 
use different labels for antigen (analyte) detection (Centi & Mascini, 2012).  
Immunoassays methods are based on the antibodies ability to bind to the 
specific structure of a molecule (Wild, 2005). The specificity and affinity of 
antibodies, when incorporated into a testing format, determine the analytical 
characteristics of the established detection system. Antibody properties are a 
crucial factor in the development of immunochemical methods (Franek, 2005). 
Therefore, optimal haptens, i.e. low-molecular weight compounds 
corresponding to the analyte of interest, need to be identified and evaluated in 
order to obtain analyte-specific antibodies.  
A hapten molecule is a small molecule which is not able to elicit the 
immune response in the animal by itself and therefore usually needs to be 
derivatised and conjugated to a larger molecule, such as a protein. The product 
of the conjugation reaction is an immunogen, which is able to elicit antibody 
formation by the animal’s immune system (Eyer & Franek, 2012).  
Antibody production is based on two major steps:  
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1) Activated hapten is covalently bound (conjugated) to a carrier 
protein to produce the immunogen. 
2) Immunisation of animals by the immunogen. The  way in which 
the hapten binds to a protein determines the character of the 
antibody specificity (Franek, 2005). It is commonly found in 
immunochemistry that the position of a chemical bridge spacer in 
the hapten structure plays a key role in antibody specificity 
(Franek, 1987).  
 
Antibodies for conventional immunoassays are usually polyclonal or 
monoclonal (Eyer, 2012; Cernoch et al., 2011). Polyclonal antibodies are 
produced by immunisation of rabbits, goats, sheep or pigs (Cernoch et al., 
2011; Hanly et al., 1995). This method is hampered by the fact that is not 
possible to produce the antibody with identical specificity even in two animals 
of the same species. Monoclonal antibodies, on the other hand, are produced by 
hybridoma technology (Hanack et al., 2016), but suffer from low predictability 
of the results (Franek, 2005). However, they can be produced in unlimited 
amounts while retaining the same properties. 
Antibodies incorporated into an immunoanalytical system can be 
characterised in terms of cross-reactivity and assay sensitivity by one of the 
most common immunoassays, ELISA. It is currently the method of choice for 
analysing a large series of samples, e.g. blood and urine samples, for 
intervention and epidemiological studies, due to its simple, quick and relatively 
inexpensive assay performance (Cernoch et al., 2011; Vass et al., 2008; 
Cespedes et al., 2006; Franek et al., 2006). To date, no ELISA method is 
available for AR, but several assays have been developed for nonylphenol, an 
analogous phenolic lipid with similarities to AR (Estévez et al., 2006; Zeravik 
et al., 2004; Franek et al., 2001). 
 
 
Enzyme-linked immunosorbent assay (ELISA) 
 
The ELISA approach is used to detect a specific antibody or antigen (analyte) 
in a sample using an enzymatic label. Horseradish peroxidase (HRP) and 
alkaline phosphatase (AP) are the enzymes most commonly used in ELISA 
systems (Cernoch et al., 2011; Vass et al., 2008; Al-Dujaili, 2006;). The 
ELISA method can be set up in variety of formats depending on nature of the 
analyte, required sensitivity, cost and availability of antigen and antibody(Centi 
& Mascini, 2012). Characterisation of antibodies can be carried out by 
competitive direct and indirect ELISA formats for detection of small molecules 
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(Figure 4), whereas assays for large molecules such as proteins are based on 
non-competitive formats such as Sandwich ELISA.  
In direct competitive ELISA, a specific antibody is immobilised on the solid 
phase (microtitre plate). After incubation, non-bound antibodies are washed 
away and free analyte and labelled tracer are added. The concentration of tracer 
is constant and free analyte is added as a standard or as an unknown sample. 
There is then competition for the binding site of the antibody between free 
analyte and labelled tracer. The amount of analyte is inversely proportional to 
the absorbance intensity of the tracer measured by spectrophotometer (Figure 
4a). The concentration of analyte is calculated from a calibration curve. 
In indirect competitive ELISA, a solid phase is coated with an immunogen 
and the specific antibodies and free analyte are added in the second step where 
the conjugated analyte on solid phase and free analyte compete for the 
antibody binding sites (Figure 4b). After incubation and washing, secondary-
labelled antibody able to bind to the specific primary antibody is added in order 
to detect the reaction signal that results from competition between conjugated 
analyte and free analyte. A lower signal is caused by higher analyte 
concentration (Figure 4b). The amount of analyte in the samples is proportional 
to the signal developed. 
 
 
a                                                     b 
                                                         
 
 
 
 
 
 
 
Figure 4. Schematic diagram of a) direct competitive enzyme-linked immunosorbent assay 
(ELISA) and b) indirect competitive ELISA, where 1 is specific antibody, 2 is tracer, 3 is free 
analyte, 4 is coated immunogen and 5 is secondary (detection) antibody labelled with enzyme. 
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2 Aims of the thesis 
The overall aim of this thesis was to develop high-throughput analytical 
methods for the analysis of alkylresorcinol metabolites and to evaluate recently 
discovered metabolites as biomarkers of whole grain wheat and rye intake. 
Specific objectives of the work performed in Papers I-IV were to: 
 
1. Develop and characterise polyclonal and monoclonal antibodies against 
two main AR metabolites, DHBA and DHPPA, and evaluate their use 
for development of a competitive ELISA system (I). 
 
2. Confirm the presence of the recently suggested AR metabolites 
DHPPTA, DHCA, DHCA-amide and DHBA-glycine and to evaluate 
their cross-reactivity in ELISA methods (I). 
 
3. Develop an optimised GC-MS method for rapid, sensitive and robust 
determination of all currently reported AR metabolites in urine (II).   
 
4. Evaluate new AR metabolites as biomarkers of whole grain rye and 
wheat intake by assessing their medium-term reproducibility and 
relative validity in 24-h urine excretion among Swedish men and 
women known to consume whole grain wheat and rye regularly (III); 
and determine their reproducibility in creatinine-adjusted spot urine in 
an independent population of middle-aged Swedish men and women 
(IV). 
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3 Materials and methods 
3.1 References compounds and enzymes 
 
Reference compounds and enzymes used in Papers I-IV are listed in Table 1.  
Table 1. Reference compounds and enzymes used in Papers I-IV 
Trivial name Supplier Purity Paper/s 
Alkylresorcinols    
C17:0, C19:0, C21:0, 
C23:0, C25:0 
Reseachem LifeScience Burgdorf, Switzerland >95% 
 
 
 
 
>95% 
I-II 
 
Metabolites 
 
 
 
Reseachem LifeScience Burgdorf, Switzerland 
 
 
DHBA
a
 I-IV 
DHPPA
b
 I-IV 
DHPAA
c
 I-II 
DHPPTA
d
  I-IV 
DHBA-glycine
e
  
 
T.Vontor, Hradec Kralove, Czech Republic 
 
 
Sigma Chemicals, St.Louis, USA 
 Reseachem LifeScience Burgdorf, Switzerland 
 
 
>98% 
* 
 
 
>98%  
>95% 
I-IV 
DHCA
1f
 I-IV 
DHCA-amide
2g
 I-IV 
 
Internal standards 
 
Syringic acid 
C20:0, C22:0, C24:0,  
C26:0 and their 
mixture 
I-IV  
II 
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Table 1 (contd.) 
Trivial name Supplier Purity Study 
    
    
Enzymes    
Type H-1 β-
glucuronidase/sulphatase 
from Helix pomatia 
Sigma-Chemicals, St. Louis, USA . I-IV 
HRP
h 
Sigma-Aldrich Chemie, Steinheim, Germany 
 
 
- I 
AP
i 
New England BioLab, United Kingdom - I 
 
Other compounds: 
 
 
  
ADHBA
3j
 T.Vontor, Hradec Kralove, Czech Republic - I 
BSA
k 
 - I 
OV
l 
Sigma-Aldrich Chemie, Steinheim, Germany - I 
TG
m 
  I 
 *The product contains 78% DHCA-amide, 17% DHCA, 5% unidentified compounds
 
1, 2, 3
 were synthesised by Ing. Vontor Hradec Kralove, Czech Republic (purity >98% and *, determined by 
NMR analysis) *78% DHCA-amide, 17% DHCA, 5% unidentified compounds)
 
a
1,3-dihydroxy-benzoic acid; 
b
3-(3,5-dihydroxyphenyl)-propanoic acid, 
c
3,5-dihydroxyphenyl acetic acid; 
d
 5-
(3,5-dihydroxyphenyl)pentanoic acid, 
e
2-(3,5-dihydroxybenzamido)acetic acid, 
f
3.5-dihydroxycinnamic acid 
and 
g
3,5-dihydroxycinnamic acid amide, 
h
horseradish peroxidase,
 i
alkaline phosphatase, 
j
4-amino-3,5-
dihydroxybenzoic acid, 
k
bovine serum albumin, 
l 
ovalbumin, 
m
porcine thyroglobulin. 
3.2 Urine sample collection and preparation 
The urine samples used for experimental work in Paper I and for biomarker 
validation and reproducibility assessment in 24-h urine collections were 
obtained from healthy, free-living Swedish men and women enrolled in a 
previous biomarker study (Marklund et al., 2013a). Urine samples from the 
DDIET-study that have been previously analysed and presented (Nowotny et 
al., 2015) were used for GC-MS method optimisation and validation in Paper 
II. The spot urine samples used to estimate biomarker reproducibility in Paper 
III were from individuals within the pilot study for the Swedish 
CArdioPulmonary bioImage Study (SCAPIS) (Nybacka et al., 2016). 
Sample preparation in Paper I, including the steps prior to direct and 
indirect ELISA and LC-MS/MS, were performed up to liquid-liquid extraction 
according to a previously reported method (Marklund et al., 2010). Samples in 
Papers III and IV were analysed according to a method described in Paper II, 
referred to as the method developed by (Wierzbicka et al., 2015). 
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An overview of the methods used for preparation of urine samples prior to 
ELISA, LC-MS/MS and GC-MS analysis is presented in Figure 5. In brief, all 
urine samples used were hydrolysed to release conjugated AR metabolites and 
the deconjugated compounds were extracted in liquid-liquid extraction. The 
pooled organic extracts were evaporated to dryness under nitrogen at 60 ºC. 
Sample extracts for immunoassay analysis were dissolved in buffer and used 
directly for direct/indirect ELISA (I). Sample extracts for LC-MS/MS analysis 
were dissolved in 150 µL water-methanol (70/30 v/v) solution, sonicated and 
transferred to HPLC vials (I). Sample extracts for GC-MS were purified on 
SPE columns, followed by deriviatisation (II-IV).  
To evaluate the most suitable hydrolysis procedure for all reported AR 
metabolites in Paper II, different enzyme concentrations (12.2, 25, 40, 50 and 
70 mU) were tested. Moreover, to determine a suitable derivatisation 
procedure, a standard sample (100 μL) was mixed with four different ratios of 
N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) and trimethylchlorosilane 
(TMCS) (70:30; 80:20; 90:10; 99:1) and incubated for 60 min, 90 min or 120 
min. The final protocol for analysis of urine samples prior to AR metabolite 
determination in Papers I-IV is presented in Figure 5. 
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Figure 5. Schematic diagram of urine sample preparation prior to ELISA, LC-MS/MS (I) and 
GC-MS/MS (II-IV). 
1
Syringic acid used as internal standard (IS) for LC-MS/MS and GC/MS 
analysis. 
2
Step evaluated in Paper II. 
3
Termination of hydrolysis and pH adjustment by addition of  
concentrated HCl (15 μL) in LC-MS/MS and GC-MS analysis. 
3.3 Alkylresorcinol metabolite determination by ELISA  
In order to develop an ELISA method for AR metabolite determination in 
human urine samples, antibodies with good analytical properties raised against 
DHBA and DHPPA compounds are needed. Development and characterisation 
of polyclonal antibodies against DHBA and DHPPA and the establishment of 
competitive direct and indirect ELISA, including optimisation and evaluation, 
was performed in Paper I. 
Urine (50µL) + IS1
Hydrolysis solution (740µL)
-0.1 M NaAC pH5 containing 25 mU β-glucuronidase from 
H.pomatia
37   ,overnight
+ Conc HCL (15µL)3
Hydrolysis2
Hydrolysed urine
Extraction
+Ethyl acetate ( 3mL)
 Vortex(2min)
 Centrifuge(3min)
 Evaporate to dryness 
x2
Ethyl acetate extract
+MeOH( 1 mL)
SPE purification
Purified AR metabolites
Silylation2
Silylated AR metabolites 
+BSTFA+ TMCS (99:1, 100µL)
• 60        
GC-MS (II-IV)
LC-MS/MS (I)
+H2O/MeOH(150µL)
(70/30, v/v)
- Sonication 10 mins
ELISA (I)
+PBS (1mL)
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  Figure 6. Schematic diagram showing development and characterisation of polyclonal 
antibodies against DHBA and DHPPA in work reported in Paper I. 
3.3.1 Immunogen preparation and characterisation 
In total, six carboxylic acid-coupled hapten-protein conjugates were prepared 
by coupling DHPPA and DHBA to bovine serum albumin (BSA),
 
ovalbumin 
(OV) and porcine thyroglobulin (TG). A derivative of DHBA with an -NH2 
group (ADHBA) was synthesised and coupled to BSA, OV and TG through an 
azo-coupling reaction. Moreover, different hapten-enzyme conjugates were 
produced by conjugation of DHBA, DHPPA and DHPAA to horseradish 
peroxidase (HRP) and alkaline phosphatase (AP) enzymes using the N-
hydroxysuccinimide/dicyclohexylcarbodiimide (NHS/DCC) method (I).  
In general, preparation of hapten-protein conjugates and hapten-enzyme 
conjugates was based on two major steps:  
1) Hapten molecule (DHBA, DHPPA), NHS and DCC were dissolved in 
dimethylformamide (DMF) buffer and the mixture was stirred overnight at 
room temperature in order to allow hapten activation. 
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.
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2) Conjugation reaction between the moiety of activated hapten and the 
amino group of the protein/enzyme molecule. The conjugates obtained were 
dialysed, purified on Sephadex G-25, lyophilised and stored at -20 °C (I). 
The immunogens obtained were subsequently characterised by ultraviolet 
(UV) absorption spectra and matrix-assisted laser desorption ionisation-time of 
flight mass spectrometry (MALDI-TOF) mass spectra, in order to confirm   
and determine the results of the conjugation reaction and to assess the hapten 
density (Figure 6). Mass spectrometric analysis was carried out using the 
Ultraflex III MALDI-TOF/TOF mass spectrometer operated in linear positive 
ion detection mode, as previously described (Cernoch et al., 2011). The 
average  number of hapten groups conjugated to BSA was calculated from the 
increase in molecular weight after conjugation of the respective hapten with 
BSA (I).  
3.3.2 Immunisation and antibody production 
Alkylresorcinol metabolites (DHBA and DHPPA) and ADHBA-protein 
conjugates were used for animal immunisation in order to elicit the animal 
immune response and to produce the polyclonal antibody (I). 
The immunogens prepared (DHBA-OV, DHBA-BSA, DHPPA-BSA, 
DHPPA-OV ADHBA-OV and ADHBA-TG) were used for rabbit 
immunisation. Each of the immunogens was injected into two rabbits and at 
one-month intervals six booster injections were administered to all 12 rabbits. 
Both indirect and direct ELISA were used for measuring the antibody titre to 
monitor the immune response, in tests performed 10-14 days after booster 
immunisation. The rabbits were exsanguinated 10 days after the last 
immunisation and the antiserum collected was stored at -20 ºC until use 
(Figure 6). 
3.3.3 ELISA for AR metabolites 
Characterisation of polyclonal antibodies raised against the above-mentioned 
AR metabolites by competitive direct and indirect ELISA was optimised by 
testing different combinations and dilutions of immobilised antibodies, coating 
conjugates and alkaline phosphatase and peroxidase tracers (Figure 6) (I). 
 
Direct ELISA  
Antibody diluted with coating buffer (200 µL) was added to wells of microtitre 
plates and incubated at 4 ºC overnight. Unbound components were removed by 
washing three times in PBST20 buffer. Standard or sample (100 µL) and 
enzyme conjugate diluted in assay buffer (100 µL) were then added to the 
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wells. After 1 hour of incubation, unbound components were removed by 
washing three times. Finally, colour signal was developed as follows:  
a) HRP conjugate  
A 200 µL aliquot of enzyme substrate solution containing 3,3’,5,5’-
tetramethylbenzidine (TMB) and H2O2 was added to each well and the 
enzymatic reaction was stopped by addition of 100 µL of 1M H2SO4. 
Absorbance was measured at 450 nm.  
b) AP conjugate 
A 200 µL aliquot of enzyme substrate (p-nitrophenyl phosphate) in 
diethanolamine buffer (DEM) was added to wells and the plates were 
incubated at 37 ºC for 60 minutes. Absorbance was measured at 405 nm. 
 
Indirect ELISA 
Hapten-protein conjugate was added to wells of microtitre plates and incubated 
overnight at 4 ºC. Unbound components were removed by washing the plate 
three times with PBST20 buffer and then 1% casein was added to the wells to 
reduce non-specific binding. The plates were washed three times, dried 
overnight at room temperature and stored at room temperature. The coating 
procedure and stabilisation by 1% casein were carried out for a large number of 
microtitre plates at the same time, in order to maintain standard performance 
conditions for a large number of samples.  The standard or the sample in PBS 
(100 µL) and antibody in PBS (100 µL) were added to the wells. The plates 
were shaken and then incubated (1 h at 4 ºC). After incubation, the ELISA 
plates were washed three times. The detection antibody conjugate swine 
immunoglobulin against rabbit immunoglobulin labelled with HRP (SWAR-
HRP) was added to each well and they were incubated again (1h, 4 ºC). The 
washing step was repeated. Enzyme substrate, chromogen and H2O2 were 
added and after 15 min the enzymatic reaction was stopped by adding 100 µL 
of 1M H2SO4. The absorbance was measured at 450 nm.  
3.3.4 ELISA evaluation 
All antibodies raised against DHBA and DHPPA metabolites were fully 
characterised in terms of specificity and assay sensitivity before the final 
selection (I). The ELISA developed was tested and evaluated for precision and 
accuracy using urine samples. Established ELISA was used to detect the 
concentration of AR metabolites in 120 urine samples from free-living 
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individuals and the results were compared against data obtained previously 
using GC-MS (Marklund et al., 2013a). 
Assay specificity was determined by testing for cross-reactivity among 
standard analytes and related compounds. Percentage of cross-reactivity (CR) 
was calculated by the equation:  
IC50 of standard analyte/IC50 of respective cross-reactant x 100 
where IC50 is the concentration of standard or competitor resulting in a 50% 
reduction of enzyme conjugate binding.  
The assay was optimised in the microtitre plate format to achieve maximum 
sensitivity. Imprecision of the ELISA method was estimated by replicate 
determination of AR metabolites in urine samples with low, medium and high 
concentrations of AR metabolites, measured in the same assay (intra-assay) or 
in different assays (inter-assay) over a one-week period. Intra-assay and inter-
assay coefficient of variation (CV) was calculated.  
 Analytical recovery was evaluated using spiked DHBA and DHPPA 
samples and percentage recovery was calculated according to the equation:  
(AR metabolite conc. measured x100)/(Measured blank + theoretical spiked 
added AR metabolite conc.) 
Limit of detection (LOD) was evaluated as:  
LOD = mean A0 + 3 x SD 
where A0 is the mean value of absorbance for n zero standards and SD is 
standard deviation of the mean absorbance. 
3.3.5 Identification and structural elucidation of cross-reactants by LC-MS/MS 
In order to investigate potential reasons for differences in results between GC-
MS and ELISA, an LC-MS/MS method was developed and employed in Paper 
I to identify potential cross-reacting compounds in human urine by identifying 
suspicious peaks in chromatograms obtained from samples showing the poorest 
agreement between the two methods. The LC-MS/MS spectra were acquired 
using different high-energy collision dissolution modes. A structure search 
using the Chem Spider database and Mass Frontier software, version 7.0 was 
conducted for interpretation of the MS/MS spectra. Reference standards for 
suspected interfering compounds (DHPPTA and DHBA-glycine) were 
purchased commercially, while DHCA and DHCA-amide were synthesised in-
house to compare standard data with those obtained in urine samples. A 
specific ELISA test was employed to confirm isomeric identity of the 
resorcinol moiety. 
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3.4 Determination of AR metabolites by GC-MS 
A previously reported GC-MS method for determination of DHBA and 
DHPPA (Marklund et al., 2010) was modified in Paper II for rapid, sensitive, 
robust and simultaneous determination of all currently reported AR metabolites 
in urine and putative biomarkers identified in Paper I. The method described in 
Paper II was used for analysis of urinary AR metabolites in Papers III and IV.  
The procedure comprises enzymatic hydrolysis of conjugated AR 
metabolites, extraction of the deconjugated compounds by liquid-liquid 
extraction, purification on SPE columns and derivatisation of AR metabolites 
as described in section 3.2 (Urine sample preparation). The derivatised urine 
samples in Papers II-IV were analysed according to the GC-MS protocol 
described in Paper II, which is referred to as the method developed by 
Wierzbicka et al. (2015). In brief, a 1.5 µL sample was injected into a GC-MS 
and quantified in electron impact-selected ion monitoring (EI-SIM) using 
molecular ions and at least one confirmatory compound specific ion. The AR 
metabolites DHBA, DHPPA, DHPPTA, DHCA, DHBA-glycine and DHCA-
amide in the urine samples were identified by comparing GC retention times 
with retention times for synthetic standards. Molecular ions were used for AR 
metabolite and internal standard quantification. 
  
GC-MS method evaluation 
 
The GC-MS method used for determination of all reported AR metabolites was 
evaluated and is described in Paper II. 
In brief, an eight-point standard calibration curve was used to establish 
calibration linearity by an internal standard method. Specificity was evaluated 
as non-interference at retention time of the respective analyte from endogenous 
matrix components and internal standard using the proposed sample 
preparation procedure and GC-MS conditions. The theoretical limit of 
detection (LOD) and limit of quantification (LOQ) were determined as the 
concentration where signal to noise ratio (S/N) was 3 and 10, respectively, 
based on S/N determined for an analyte with low endogenous concentration in 
a sample. Precision was estimated by replicate determinations (n=3) for 
analytes in urine samples at low, medium and high concentrations, measured 
within the same assay (intra-assay) or in different assays performed over a one-
week period (inter-assay). The recovery was evaluated by spiking quality 
control urine samples with three concentrations covering expected low, 
medium and high analyte concentrations in authentic samples. Four replicate 
samples were prepared at each spiking level. Moreover, to ensure method 
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stability, triplicate samples of two different quality control urines were 
included in each batch (III and IV). 
3.5 Statistical analysis 
In Paper II, differences between the silylation reagents were evaluated using 
general linear model (GML) with BSTFA/TMCS ratios and incubation times 
entered as fixed factors. Linear regression was applied to examine the stability 
of the AR metabolites by entering time (days) as a continuous variable and 
sample concentration (n=4 levels) as a fixed factor. Minitab 16 (State College, 
PA, USA) was used for statistical analysis and P<0.05 was considered 
statistically significant. 
In Paper III, differences in intake and urinary excretion between occasions 
were evaluated by paired t-test. In paper IV paired t-test was used to evaluate 
differences in creatinine-adjusted metabolite concentrations in spot-urine 
samples between occasions.  Spearman´s rank correlation coefficient (rs) was 
calculated to examine the relationship between AR metabolites in urine and 
AR homologues in plasma. Moreover, to investigate how the individual AR 
metabolites in urine were related to each other, Spearman’s rank correlations 
coefficient was calculated for the two occasions. The medium-term  
reproducibility of urinary AR metabolites excretion was assessed by 
calculating their ICC and 95% confidence interval (CI) (III and IV). The 
relative validity of urinary AR metabolites was assessed by calculating 
Spearman’s rank correlation coefficient for whole grain intake, AR intake and 
AR metabolite urinary excretion on the same occasion, different occasions and 
mean of occasions. To assess the recovery across different intakes (III), a test 
for trends was conducted by GLM with log-transformed metabolite recovery as 
dependent variable and quartile median AR intake as independent variable. In 
addition, multiple linear regression models were used in order to evaluate 
associations between reported whole grain intake (independent variable) and 
log-transformed creatinine adjusted urinary AR metabolites (dependent 
variable) adjusted for confounding factors. Confounding factors were selected 
after analyzing Spearman’s rank correlation coefficients between urinary AR 
metabolites and previously suggested confounding factors such as sex, age and 
BMI. Confounders were included if they were significantly correlated with 
urinary AR metabolit cocentrations (IV). All statistical analyses were 
performed using SAS v.9.1 (SAS Institute) and P<0.05 was considered 
statistically significant. 
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4 Results and discussion 
4.1 Quantification of Alkylresorcinol metabolites in urine by ELISA 
When this PhD project started, DHBA and DHPPA were the only known 
urinary metabolites of AR. 
In Paper I, polyclonal antibodies against DHBA and DHPPA were 
developed, incorporated into enzyme-linked immunosorbent assay (ELISA) 
formats and characterised in terms of assay sensitivity, cross-reactivity, 
precision and accuracy. The optimised ELISA method was used for 
determination of AR metabolites in 120 urine samples taken from intervention 
and/or cross-sectional studies previously analysed by GC-MS. At this point, 
the other metabolites (DHPPTA, DHCA, DHCA-amide, DHBA-glycine) were 
found to contribute to ELISA. 
4.1.1 Immunogen preparation and characterisation 
Immunogens were successfully prepared by conjugation of the carboxyl group 
in DHBA and DHPPA metabolites with amino groups in BSA and OV protein. 
In this case, the 3,5 dihydroxyphenyl moiety was considered an 
immunodominant determinant. Hence, antibodies with high specificity towards 
that area were expected. Moreover, 4-amino-3,5-dihydroxybenzoic acid 
(ADHBA) was successfully conjugated to OV and TG proteins, in order to 
obtain antibodies towards the carboxyphenyl moiety. In this case, the carboxyl 
group was situated in an immunodominant position and thus high specificity 
towards this side of the ADHBA molecule was anticipated (Figure 7).  
The absorption spectra of DHPPA-BSA and DHPPA-OV conjugates 
showed symmetrical peaks at 280 nm, whereas surprisingly, the conjugates 
having DHBA hapten linked to the same carrier proteins exhibited spectrum 
shifted to longer wavelengths (285-350 nm). The spectral change in the DHBA 
hapten was ascribed to the electron-withdrawing effect of the carbonyl function 
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in the peptide bond (-CONH-) resulting in hydroxyl ionisation in the resorcinol 
moiety. On the other hand, the longer aliphatic chain CH2-CH2-CONH- in 
DHPPA-protein conjugate contributed to neutral ionisation state of the 
hydroxyl groups through the electron-donating effect. Hapten density rate for 
the DHBA-, DHPPA- and DHBA-azo-BSA was 39.8, 26.9 and 1.5 (mol/mol), 
respectively. Hapten density for OV conjugates was not measured because 
MALDI-TOF/TOF mass analysis did not provide a suitable spectral 
characteristic. 
 
Figure 7. Recognition strategy schematically depicted for DHBA, DHPPA and 4-Amino-3,5-
dihydroxybenzoic acid ( ADHBA) hapten protein conjugates. In the hapten design, the upper 
DHBA, DHPPA structures are bound to carrier protein via a carboxyl group which is a natural 
part of the molecules. Aliphatic chains of the molecules serve here as a spacer by which the 
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haptens are linked to carrier proteins. According to immunochemical theory, the areas of the 
hapten removed from the spacer mostly have a high degree of specificity (3,5-dihydroxyphenyl 
moiety), while the vicinity of the spacer is typified by low specificity (cross-reactivity). Hapten 
with a short spacer azo group between two hydroxy groups was designed to achieve high 
specificity towards the opposite side of the ADHBA molecule (carboxyphenyl moiety). Hatched 
curves represent antigen binding site of the antibody. 
4.1.2 Antibody production and assay optimisation 
Polyclonal antibodies raised against DHBA and DHPPA exhibited a titre 
higher than 1/2000 and showed promising binding characteristics in the 
indirect ELISA. Therefore, the indirect format was initially used for antibody 
characterisation. However, it was not possible to achieve a stable and robust 
assay, even though great efforts were made by testing various blocking agents, 
coating conditions and incubation times and temperatures. Based on these 
observations, a direct ELISA system was further investigated. This format 
proved to be more stable and less sensitive to temperature changes and to other 
unpredictable factors. Direct ELISA was used for antibody characterisation and 
subsequently for DHBA and DHPPA quantification in human urine samples.   
The ELISA employing alkaline phosphatase (AP) conjugates exhibited 
good calibration curves, whereas peroxidase conjugates were surprisingly not 
recognised by the corresponding antibodies. 
The DHBA-azo-immunogens with low hapten density produced antibodies 
with strong binding to immunogen and negligible analyte displacement, and 
hence they were excluded from further evaluations. Table 2 summarises results 
of the optimised assays for DHPPA and DHBA quantification. 
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Table 2.  Optimised ELISA systems for DHBA and DHPPA determination developed in Paper I 
Direct ELISA 
a     
Coating antibody Antibody dilution AP conjugate AP conjugate 
dilution 
IC50 
(µmol/L) 
Anti DHPPA-OV 1:500 DHPPA-AP 1:500 4.93 
Anti DHPPA-
BSA 
1:10 000 DHPPA-AP 1:5000 1.80 
Anti DHBA-OV 1:5000 DHBA- AP 1:5000 1.76 
Indirect ELISA     
Antibody  Antibody dilution Coating 
conjugate 
Conjugate 
dilution
a 
IC50 (µmol/L) 
 
Anti DHPPA-OV 1:20 000 DHPPA-BSA 1:10 000 1.30 
Anti DHPPA-
BSA 
1:10 000 DHBA-OV 1:20 000 8.33 
Anti DHBA-OV 1:50 000 DHBA-BSA 1:50 000 5.42 
a
Concentration of coating conjugate prior to dilution was 0.2 mg/mL.  
*Each antibody was obtained from one rabbit. 
b
IC50 was determined from duplicate wells in multiple experiments (n=6) over a period of 8 weeks 
4.1.3 Evaluation of ELISA and method comparison 
At the start of the study, the specificity of the antibodies in optimised assays 
was tested by measuring cross-reactivity among DHPPA or DHBA as standard 
analytes and for chemically related compounds, including AR homologues. 
The antibody raised against DHPPA showed relatively low cross-reactivity 
with 3,5-dihydroxyphenyl acetic acid (DHPAA) (12 and 20%) in both direct 
and indirect formats and negligible reactivity with DHBA and intact ARs. 
Because DHPAA is not a product of AR metabolism and dietary precursors of 
DHPAA are minor, it is unlikely that it will cause interferences in the ELISA 
for DHPPA in body fluids. In addition, negligible cross-reactivity between 
DHPPA and DHBA can be associated with ionisation state of the resorcinol 
OH- groups, as deduced from the absorption spectra. It can be postulated that 
the antibody primarily distinguished various degrees of ionisation of hydroxyl 
groups in AR, whereas chemical differences in the site of conjugation (-COOH 
versus CH2-CH2-COOH) were not recognised by the antibody.  
Direct ELISA based on the antibody against DHBA showed 19% cross-
reactivity with DHPPA, whereas cross-reactivity with other structurally related 
compounds tested was below 2%. As expected, the cross-reactivity with ferulic 
acid in all reagent combinations was negligible.  
Standard curves constructed for metabolites were in the range 0.005-55 
µmol/L and were suitable for quantification of DHBA and DHPPA in urine 
samples after 20-fold dilution in order to reduce potential matrix interferences. 
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The direct ELISA developed was evaluated in terms of assay sensitivity, 
precision and recovery. The results obtained were acceptable for determination 
of both metabolites and are presented in Table 3. 
Table 3. Performance analytical parameters of the ELISA method described in Paper I 
.Metabolite LOD
1 
[µmol/L] 
IntraCV
2 
[%] 
InterCV
2 
[%] 
Recovery
 
[%] 
 DHBA 0.09 1.3-9.4 3.5-20 102
a
 
DHPPA 0.06
 
0.7-7.2 5.1-11.5 104
b
 
1 
Determined in phosphate buffer saline (PBS) by direct ELISA. 
 
2
Samples (n=3) having low, medium and high concentrations of both metabolites were measured, each sample 
was prepared in triplicate. 
a
Mean recovery of the concentrations tested (0.64, 3.24, 12.97 µmol/L). 
b
Mean recovery of all concentration tested (0.54, 2.74, 10.97 µmol/L).  
 
In the method comparison, AR metabolite concentrations in urine measured by 
ELISA were observed to be three- to five-fold higher by GC-MS (r
2
=0.09 and 
r
2
=0.31 for DHBA and DHPPA, respectively). Poor agreement between those 
methods (Figure 8) was probably due to presence of other and unknown 
compounds such as newly discovered DHPPTA, DHBA-glycine and sulphated 
conjugate of DHCA (Zhu et al., 2014; Bondia-Pons et al., 2013). 
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Figure 8. Correlation between concentrations of (left) 3,5-dihydroxybenzoic acid (DHBA) and 
(right) 3-(3,5-dihydroxyphenyl)-propanoic acid (DHPPA) determined in 111 urine samples by 
direct ELISA and GC-MS. 
4.1.4 Further testing of ELISA cross-reactivity of identified resorcinolic 
compounds 
Two putative alkylresorcinol-derived metabolites, DHCA and DHCA-amide, 
identified by LC-MS/MS in Paper I and DHPPTA and DHBA-glycine (Figure 
9), recently reported as AR metabolites (Zhu et al., 2014), showed high cross-
reactivity in the antibodies developed against DHBA and DHPPA (Table 4). 
The chemical identities of the new compounds were confirmed in Paper I by 
comparing retention times and spectra with those of reference standards. 
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Figure9. Chemical structure of new putative AR metabolites: DHPPTA, 5-(3,5-dihydroxyphenyl) 
pentanoic acid; DHCA, 3,5-dihydroxycinnamic acid, DHCA-amide, 3,5-dihydroxycinnamic acid 
amide, DHBA-glycine, 2-(3,5-dihydroxybenzamido)acetic acid. 
 The 3,5-DHCA molecule, as well as 3,5-DHCA-amide and DHBA-glycine, 
have a planar structure due to a conjugated π electron system as the DHBA 
hapten attaches to the immunogen via a peptide linkage. Therefore these three 
compounds exhibited a strong ELISA response with antibodies against DHBA 
(cross-reactivity was 115, 420 and 5000%, respectively) (Table 4). 
Moreover, the structure of isomeric 3,4-DHCA did not elicit any 
measurable response to the compound in the ELISA test, thus showing that the 
antibody can specifically recognise only the 3,5-dihydroxyphenyl (resorcinol) 
moiety in the molecules. On the other hand, the peptide bond in DHPPA-
protein conjugates does not hinder rotation of the resorcinol group and thus 
does not result in a planar system. As expected, antibodies raised against 
DHPPA showed very low cross-reactivity with DHBA-glycine, which has a 
planar structure, as well as DHBA, DHCA and DHCA-amide. Moreover, 
cross-reactivity of the prepared antisera was associated with ionisation state of 
the resorcinol OH- groups deduced from the absorption spectra, as mentioned 
above. One can speculate that the antibodies are able to distinguish various 
ionisation degrees of hydroxyl groups in the AR structures.  
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Table 4. Cross-reactivity among selected compounds in direct ELISA 
                Reagent combination 
Compound Anti DHPPA-BSA 
DHPAA-AP 
Anti DHBA-OV 
DHBA-AP 
               Cross-reactivity (%)* 
DHCA          12          115 
DHCA-amide          60          420 
DHPPTA          26           11 
DHBA-glycine           1         5000 
*Number of experiments performed n = 3 
4.2 Quantification of DHBBA, DHPPA and new alkylresorcinol 
metabolites in urine by GC-MS 
A modified method based on Marklund et al. (2010) was developed in Paper II 
to determine AR metabolites (DHBA, DHPPA) along with two novel 
(DHPPTA and DHBA-glycine) and two putative AR metabolites (DHCA and 
DHCA-amide).  
Chromatographic separation for all recently reported AR metabolites was 
obtained within 7 min (Figure 10), which is 9 min shorter than with existing 
methods (Marklund et al., 2010).  
The method described did not show any apparent interference for AR 
metabolites or for the internal standard when analysed in blank and spiked 
urine samples for detected AR metabolites. The optimised GC-MS conditions 
were applied to a large number of samples. Sensitivity of the method is highly 
dependent on the instrument conditions and therefore maintenance of the 
established GC-MS conditions was performed every 200 injections. The limit 
of quantification, recovery and precision of the GC-MS method developed 
were satisfactory (Table 5). Moreover, statistical evaluation of the effect of a 
four-day time period and concentration interaction revealed no significant 
influence on the stability of AR metabolite concentrations.  
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Figure 10. Total ion chromatogram (TIC) and selected ion monitoring (SIM) chromatograms for 
molecular ions from DHBA, SA, DHPPA, DHPPTA, DHCA, DHCA-amide and DHBA-glycine  
in (left) standard solution and (right) a blank urine sample treated according to the experimental 
protocol. 
The most suitable enzyme concentration for simultaneous hydrolysis of 
DHBA, DHPPA, DHPPTA, DHBA-glycine, DHCA and DHCA-amide was 
optimised and was found to be 25 mU β-glucuronidase from H. pomatia. 
Detected concentrations of DHPPTA, DHCA and DHCA-amide were much 
higher after the deconjugation procedure compared with the procedure with no 
deconjugation step. These results confirm that DHPPTA, DHCA and DHCA-
amide are present in urine in the free form or as a conjugates, as reported 
previously for DHBA and DHPPA (Marklund et al., 2010(Koskela, 2007 
#410). Moreover, the deconjugation step did not affect DHBA-glycine, which 
shows that this molecule is not sulphated or glucuronidated. 
In order to obtain the highest efficiency of the silylation procedure, several 
conditions, i.e. effects of BSTFA/TMCS ratio and time of incubation for 
DHPPTA, DHCA, DHCA-amide and DHBA-glycine, were systematically 
evaluated. The results showed that all AR metabolites were similarly 
derivatised under all conditions tested. In the final protocol, a BSTFA/TMCS 
ratio of 99:1 was used (Figure 5), since a 70:30 ratio could cause 
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contamination of the GC-MS and problems with the syringe injection. 
Moreover, 70 min, which was 10 min longer than in the previous method, was 
a sufficient time for derivatisation of all AR metabolites. When several sample 
batches need to be analysed, the derivatisation step should preferably be 
conducted at the same time for all batches to lower the inter-batch variation. 
 
Table 5. Parameters for GC-MS method validation described in Paper II 
AR metabolite Parameters 
 LOD
1 
µmolL
-1 
Recovery
2 
% 
IntraCV
3 
% 
InterCV
4 
% 
DHBA 0.3 108 8.9 13.1 
DHPPA 1.5 90 2.9 9.3 
DHCA 0.1 97 4.8 10.8 
DHPPTA 0.1 80 8.8 4.3 
DHCA-amide 0.4 75 9.0 6.7 
DHBA-glycine 0.1 88 7.4 11.4 
1
Limit of detection was determined as the concentration where signal to noise ratio (S/N) was 3. 
2
The recovery was evaluated by spiking quality control urine samples with three contents covering expected 
low, medium and high analyte concentrations in authentic samples. 
3
Intraassay CV (mean) was determined from the intrassay CV of three occasions from batch 1. 
4
Interassay CV (mean) was determined from the interassay CV from three occasions. 
4.3 Evaluation of the new alkylresorcinol metabolites as dietary 
biomarkers 
The new suggested AR metabolites DHPPTA, DHCA, DHBA-glycine and 
DHCA-amide, quantified according to the method described in Paper II, were 
evaluated as biomarkers of whole grain rye and wheat intake by assessing the 
medium-term reproducibility and relative validity in 24-h urine samples from a 
Swedish free-living population (Paper III) and by determination of their 
reproducibility in spot urine samples after adjustment of creatinine and 
correlation with intake in a population of middle-aged Swedish men and 
women (Paper IV). 
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4.3.1 Excretion and reproducibility of Alkylresorcinol metabolites 
 
Paper III 
 
Urinary excretion of AR metabolites did not differ significantly between the 
first and second occasion (P>0.05) except for DHCA-amide, for which 
excretion was higher on the second occasion (P<0.05). DHBA and DHPPA 
urinary excretion was similar to that in a previous study based on the same 
participants (Marklund et al., 2013a) and comparable to that in a study on 
Finnish women (Aubertin-Leheudre et al., 2010). The highest urinary excretion 
among confirmed and putative AR metabolites was found for DHCA-amide, 
followed by DHPPA, DHBA, DHCA, DHBA-glycine and DHPPTA. The 
concentration of DHCA-amide was considerably higher than that of the other 
AR metabolites and the recovery of excreted DHCA-amide exceeded 891 % of 
the ingested AR dose. This strongly suggests the presence of additional dietary 
precursors along with AR. The proportion of the individual metabolite in total 
urinary AR metabolite excretion (sum of DHPPA, DHBA, DHCA, DHBA-
glycine and DHPPTA) was: DHPPA 42%, DHBA 33%, DHCA 13%, DHBA-
glycine 9% and DHPPTA 2% (Figure 11). 
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Figure 21. Proportion of the individual alkylresorcinol (AR) metabolites in total 24-h urinary AR 
metabolite excretion obtained in Paper III. 
The different metabolites were well correlated with each other: DHBA r= 0.43-
0.78, DHPPA r=0.34-0.78, DHCA r=0.50-0.81, DHPPTA r=0.25-0.81, and 
DHBA-glycine r=0.34-0.69. DHCA-amide correlated only with DHBA-
glycine (r=0.69) and DHPPTA (r=0.25). Moreover, modest to strong 
correlations between different putative and novel AR metabolites and AR 
homologues in plasma were observed. This is indirect evidence that they are all 
metabolites of intact AR homologues (Landberg et al., 2009; Ross et al., 2004).  
The reproducibility for DHCA, DHPPTA and DHBA-glycine estimated in 
Paper III was good to excellent and appeared somewhat higher than that of 
DHPPA and DHBA. The highest reproducibility was shown by DHCA and 
DHPPTA (ICC = 0.63, 95% CI = 0.49-0.75 for both). This can be due to longer 
half-life of these components, as indicated in a previous study (Zhu et al., 
2014).   
The reproducibility of DHBA and DHPPA in 24-h urine samples was 
similar to that previously reported for DHBA and DHPPA (Marklund et al., 
2013a) and fasting plasma AR concentration (Andersson et al., 2011b), but 
higher than for fasting plasma AR metabolites (Montonen et al., 2012).  
In comparison, medium-term reproducibility of all currently reported AR 
metabolites investigated in this thesis was similar to or higher than that 
42%
33%
13%
9%
2%
DHPPA
DHBA
DHCA
DHBA-glycine
D
H
P
P
T
A
55 
observed for the other biomarkers used in epidemiological studies, such as 
plasma carotenoids, vitamin D analytes and enterolactone (Kotsopoulos et al., 
2010). 
 
Paper IV 
In Paper IV, AR metabolite concentrations were measured in a second batch of 
spot urine samples and adjusted for creatinine concentration. The highest 
concentrations were found for DHBA and DHPPA, followed by DHCA, 
DHBA-glycine and DHPPTA. The DHBA and DHPPA concentrations 
measured in Paper IV appeared to be in the same range as in Paper III and 
double those found in spot urine samples from US women (Landberg et al., 
2012). The relative proportion of the AR metabolites was 33%, 33%, 16%, 
14% and 4% for DHBA, DHPPA, DHCA, DHBA-glycine and DHPPTA, 
respectively (Figure 12), which is comparable to that found in Paper III. 
 
 
Figure 32. Proportion of the individual alkylresorcinol (AR) metabolites in total AR metabolite 
excretion measured in spot urine samples obtained in Paper IV. 
The results showed that creatinine-adjusted AR metabolites in spot urine were 
highly correlated with each other (r=0.46-0.83, P<0.001). The only exception 
was DHPPTA, which was not correlated with DHPPA (r=0.17, P>0.05) and 
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modestly correlated with DHBA and DHBA-glycine. The strongest correlation 
was found for DHCA (r=0.68-0.81). The significant correlation between the 
recently suggested AR metabolites (DHCA, DHBA-glycine and DHPPTA) and 
established AR metabolites (DHBA and DHPPA), along with the presence of 
their free and/or conjugated forms in urine after controlled whole grain wheat 
and rye intake (Zhu et al., 2014; Bondia-Pons et al., 2013), strongly suggests 
they are AR metabolites. However, the structure of the DHCA molecule 
suggests that biochemically, this compound cannot be formed through the 
established hepatic AR metabolism pathway. 
The reproducibility of AR metabolites in spot urine determined in Paper IV 
was similar to that previously reported for DHBA and DHPPA in 24-h 
excretions (Marklund et al., 2013a) or higher than that shown for DHBA and 
DHPPA in creatinine-adjusted spot urine (Marklund et al., 2013a; Landberg et 
al., 2012). Moreover, the reproducibility of the new AR metabolites (DHCA, 
DHBA-glycine and DHPPTA) in spot urine samples taken two weeks apart 
was compared with the reproducibility of the same metabolites in two 24-h 
urine collections taken 2-3 months apart in a population with a wide intake 
range in Paper III. The results were of the same magnitude (or slightly higher 
for the new metabolites), probably because of smaller fluctuations resulting 
from shorter time interval between samplings.   
4.3.2 Relative validity and determinats beyond intake 
 
Paper III 
 
The 24-h urine excretion of DHBA, DHPPA, DHCA, DHPPTA was 
significantly correlated to self-reported intake of total whole grain, whole grain 
rye and whole grain rye + wheat, irrespective of when intake and excretion 
were measured. DHBA-glycine was only correlated to whole grain rye and 
whole grain rye+ wheat intake, where the intake was measured on the first 
occasion. The poor correlation between DHBA-glycine and other AR 
metabolites suggests that this metabolite may have other, more important, 
precursors than AR. It could also be the case that DHBA-glycine is more 
extensively excreted through bile and therefore urinary DHBA-glycine shows 
lower correlations with other urinary AR metabolites and AR intake. 
Spearman's rank correlation coefficient calculated for whole grain rye 
intake on the first occasion and metabolite excretion was highest for the new 
putative AR metabolite DHCA (rs = 0.61-0.66), followed by DHPPA (rs=0.56-
0.66) and DHBA (rs=0.54-0.67). These results were similar to those in studies 
where whole grain intake was estimated by weighed food records (Marklund et 
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al., 2013a; Aubertin-Leheudre et al., 2010b) and higher than in studies where 
biomarker measurement was correlated with long-term intake assessment 
methods, e.g FFQ (Landberg et al., 2012). Correlations between whole grain 
wheat intake and urinary metabolites were weak and in most cases absent. The 
good correlation between whole grain rye and weak correlation between whole 
grain wheat was probably because rye was the main source of whole grain 
intake, with unstable and low wheat intake, in the population studied (Paper 
III). Further studies based on participants with higher and more stable wheat 
intake might provide a better correlation between AR urinary excretion and 
whole grain wheat intake.  
In general, AR metabolites were not correlated with whole grain oats, 
barley, maize or rice. Any slight correlations observed can be due to the minor 
dietary source of DHBA and DHPPA detected in the non-AR-containing 
cereals (Landberg et al., 2009a). 
The strong correlation observed between AR metabolite excretion and AR 
intake was probably due to the fact that rye contains high amount of AR and 
was the main source of whole grain in Paper III. 
Recovery of ingested AR excreted as metabolites in urine was higher in 
participants with lower AR intake. This pattern has also been observed in other 
studies (Landberg et al., 2009d). It can be explained by a change in the 
elimination route and decreased absorption with high doses. 
 
Paper IV 
The results of Paper IV showed that AR metabolites were correlated with 
intake. However when investigating their independent association with whole 
grain intake, only DHBA, DHCA and DHBA-glycine were associated. This is 
because sex and age were independently associated and found to be possible 
confounders of the intake in the Spearman correlation analyses. The sex-related 
differences in AR metabolism were also suggested by Marklund et 
al(Marklund et al., 2012) and have been observed for γ-tocopherols (Frank et 
al., 2008). The results in Paper IV support the idea that sex is a strong 
independent predictor and should be taken into account when applying urinary 
AR metabolites as biomarkers.   
The results of Papers III and IV suggest that DHCA and DHPPTA 
measured in a single 24-h urine sample and one or several spot urine samples 
may be used as a medium to long-term biomarker of whole grain wheat and rye 
intake. However, this should be confirmed in populations with lower whole 
grain intake before testing the applicability of these metabolites as biomarkers 
in large epidemiological studies. 
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4.3.3 General discussion 
At the start of this PhD project, the only known AR metabolites were DHBA 
and DHPPA. Previous studies have suggested that these metabolites have a 
longer half-life than intact AR (Soderholm et al., 2009) and that their 24-h 
excretion correlates well with estimated intake in a dose-dependent manner 
(Landberg et al., 2009d). Based on this, they have potential as dietary 
biomarkers. Therefore polyclonal antibodies against these metabolites were 
developed and optimised in this thesis in order to obtain a simple and 
inexpensive method for analysing a large number of samples for 
epidemiological studies. Paper I showed that antibodies developed against 
DHBA and DHPPA exhibited high cross-reactivity. When investigating this 
further, it was found that identified compounds with structural similarities 
(DHCA, DHCA-amide, DHPPTA and DHBA-glycine, identified as potential 
AR metabolites by others) showed high cross-reactivity (Zhu et al., 2014; 
Bondia-Pons et al., 2013). Antibodies against DHBA exhibited high cross-
reactivity against DHCA, DHCA-amide and DHBA-glycine (115, 420 and 
5000 %, respectively). Slight cross-reactivity was also observed for antibodies 
against DHBA metabolites with DHPPA. Current knowledge considering the 
presence of the new putative AR metabolites in urine, their structure and their 
role as cross-reactants in the assays developed in Paper I probably explains the 
lack of agreement between ELISA and GC-MS results. It remains to be 
determined whether ELISA can be applied for quantification of AR 
metabolites in urine samples after taking the new knowledge about cross-
reacting compounds into account. Purification or fractionation of sample 
extracts could potentially be applied, and/or correction models taking 
differences in cross-relativity of different metabolites into account.   
Establishment of a valid GC-MS method (Paper II) allows accurate 
determination of different metabolites and could thus provide valid data for 
development of correction models for ELISA and for use in evaluation of the 
new metabolites as biomarkers. 
 Among the new metabolites identified (Papers III and IV), DHCA was 
identified as a likely AR metabolite based on its correlation with other AR 
metabolites and with plasma AR concentrations and the intake of whole grain 
wheat and rye (Paper III). DHCA has also been found in urine as a sulphate 
conjugate after controlled rye intake (Bondia-Pons et al., 2013). However, the 
double bond between carbon 2 and 3 in the propionic acid part of the molecule 
suggests that this compound cannot be formed through the established hepatic 
AR metabolism pathway (Ross et al., 2004c). It remains to be determined how 
this metabolite is formed. Moreover, DHCA-amide was present in high 
concentrations in urine in Papers III and IV, but it was generally poorly 
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correlated with other AR metabolites, plasma AR concentration and whole 
grain wheat and rye intake, and was found in higher amounts in urinary 24-h 
excretion than the corresponding AR ingested. Thus, it appears that this 
molecule is derived from other sources than AR, or at least has major 
determinants other than AR. Based on this, it should not be further evaluated as 
a biomarker of whole grain wheat and rye intake.   
Papers III and IV showed that the new putative AR metabolites in 24-h 
urine collections and spot urine samples had good to excellent reproducibility 
and that they were in general as well or better correlated to intake than existing 
biomarkers. An exception was DHBA-glycine, where a weak correlation with 
whole grain intake and no correlation with AR intake was observed (Paper III). 
This can be due to the fact that this metabolite can have other precursor than 
AR, or that it may be affected by non-dietary determinants or can be more 
readily excreted in bile. However, when considering using DHCA, DHPPTA 
and DHBA-glycine as biomarkers of whole grain intake, future studies should 
be performed in populations with lower whole grain intake before the 
biomarkers are tested in relation to endpoints in epidemiological studies. This 
is particularly important since Paper IV indicated that age and sex influenced 
the validity of AR metabolites in spot urine samples and therefore should be 
taken into account when using urinary AR metabolites as biomarkers. Other 
determinants may also play a role in different populations and should therefore 
be evaluated. 
In conclusion, the results presented in Papers III and IV support the 
suggestion that new AR metabolites, particularly DHCA, appear promising as 
a biomarker of whole grain wheat and rye intake in populations where these 
cereals are consumed frequently and regularly. It remains to be determined 
whether these new putative biomarkers can be used in combination with 
traditional dietary assessment methods to improve intake estimations and 
reduce sample requirements (Freedman et al., 2010). Moreover, as already 
mentioned, AR metabolites together with plasma AR can be used to measure 
dietary compliance in dietary intervention studies and especially to monitor 
compliance within individuals over treatment periods.  
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5 Main findings 
 Lack of agreement between  ELISA and GC-MS was observed, due to the 
presence of as yet unknown metabolites which cause a high degree of cross-
reactivity with the antibodies developed (Paper I) 
 Cross-reactivity is likely caused by the presence of DHPPTA, DHCA, 
DHBA-glycine and DHCA-amide and possibly by additional yet unknown 
compounds (Paper I). 
 A GC-MS method for rapid, sensitive and robust determination of all 
currently reported AR metabolites in urine was developed (Paper II) and 
applied in biomarker evaluation studies (Papers III and IV). 
 The medium-term reproducibility of DHCA, DHPPTA and DHBA-glycine 
in 24-h urine samples was found to be moderate to excellent. DHCA and 
DHPPTA metabolites correlated well with self-reported whole grain rye 
and wheat intake. This suggests that measurement of DHCA and DHPPTA 
excretion in a single 24-h urine sample may adequately reflect medium to 
long-term whole grain wheat and rye intake and thus they have potential as 
biomarkers in populations with similar intake patterns (Paper III). 
 The reproducibility of DHCA, DHPTTA and DHBA-glycine in single-spot 
urine samples after creatinine adjustment determined in an independent 
population of middle-aged Swedish men and women over a period of 2 
weeks was good. The results suggested that AR metabolites determined in a 
single or duplicate spot urine samples could be useful biomarkers of whole 
grain intake (Paper IV). 
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6 Future research 
 
 Studies to evaluate the performance of the assay developed after different 
purification or fractionation steps could be undertaken. Correction models 
based on relative metabolite abundance and cross-reactivity could also be 
tested. 
 More effort could be focused on identification and validation of other 
possible compounds as cross-reactants in urine, in order to utilise the 
ELISA method for quantification of AR metabolites in urine samples. 
 Animal feeding and cell studies with pure AR homologues need to be 
performed, in order to confirm DHCA and DHBA-glycine as AR 
metabolites. Moreover, alternative intake sources of these compounds 
should be identified.  
 To confirm the usefulness of new AR metabolites (particularly DHCA) in 
24-h and spot urine collections as dietary biomarkers of whole grain wheat 
and rye, further studies in populations with lower intake are needed. 
 Human pharmacokinetic studies should be performed in order to determine 
the half-life of new putative AR metabolites (DHCA, DHPPTA, DHCA-
glycine and DHCA-amide) as a possible long-term biomarker of whole 
grain intake. 
 Alkylresorcinols or other compounds in adipose tissue could be evaluated 
as more long-term biomarkers of whole grain wheat and rye intake. 
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